The Committee for Medicinal Products for Human Use today issued a positive opinion for the use of Victoza (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments.

Renal impairment is a challenging and common long-term complication of type 2 diabetes that requires frequent monitoring of blood glucose levels and kidney function. Depending on age, duration of diabetes and blood glucose control, up to 40% of people with type 2 diabetes will develop some degree of renal impairment.

For more details, go to: http://www.novonordisk.com/press/sea/novo-nordisk-news.asp?sShowNewsItemGUID=fd409ce9-0a52-46da-a6e2-780c55bf6923&sShowLanguageCode=en-GB